MCID: PNC035
MIFTS: 82

Pancreatic Cancer malady

Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases, Endocrine diseases categories

Aliases & Classifications for Pancreatic Cancer

About this section
Sources:
46OMIM, 30LifeMap Discovery®, 8Disease Ontology, 9diseasecard, 42NIH Rare Diseases, 20GeneTests, 10DISEASES, 44Novoseek, 48Orphanet, 22GTR, 32MedlinePlus, 61UMLS, 56SNOMED-CT, 39NCIt, 33MeSH, 27ICD9CM, 34MESH via Orphanet, 26ICD10 via Orphanet, 62UMLS via Orphanet, 25ICD10
See all sources

Aliases & Descriptions for Pancreatic Cancer:

Name: Pancreatic Cancer 46 30 8 9 42 10 44 48 32
Pancreatic Carcinoma, Familial 42 20 22 61
Pancreatic Carcinoma 8 44 48 61
Malignant Neoplasm of Body of Pancreas 8 61
Malignant Neoplasm of Head of Pancreas 8 61
Malignant Neoplasm of Tail of Pancreas 8 61
Familial Pancreatic Carcinoma 42 48
Pancreatic Cancer, Somatic 46 9
Familial Pancreatic Cancer 42 48
Pancreatic Neoplasm 8 61
Pancreatic Tumor 8 44
 
Cancer Pancreas 42 22
Malignant Neoplasm of Pancreas 61
Pancreatic Carcinoma, Somatic 46
Exocrine Pancreas Carcinoma 8
Cancer of the Pancreas 42
Carcinoma of Pancreas 8
Ca Head of Pancreas 8
Ca Body of Pancreas 8
Ca Tail of Pancreas 8
Pancreatic Cancer 2 22
Pancreas Neoplasm 8


Classifications:



Characteristics (Orphanet epidemiological data):

48
pancreatic cancer:
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Adult
familial pancreatic carcinoma:
Age of onset: Adult


External Ids:

Disease Ontology8 DOID:1793, DOID:4905
NCIt39 C3305, C3850
ICD9CM27 157
Orphanet48 217074, 1333
MESH via Orphanet34 D010190, C535837
ICD10 via Orphanet26 C25
UMLS via Orphanet62 C0235974, C2931038

Summaries for Pancreatic Cancer

About this section
OMIM:46 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less... (260350) more...

MalaCards based summary: Pancreatic Cancer, also known as pancreatic carcinoma, familial, is related to pancreatitis and adenocarcinoma, and has symptoms including neoplasm of the pancreas An important gene associated with Pancreatic Cancer is SMAD4 (SMAD family member 4), and among its related pathways are Integrated Breast Cancer Pathway and Integrated Pancreatic Cancer Pathway. The drugs ifosfamide and irinotecan and the compounds serine and vegf have been mentioned in the context of this disorder. Affiliated tissues include the pancreas, pancreas and endothelial, and related mouse phenotypes are mortality/aging and cellular.

Disease Ontology:8 An endocrine gland cancer located in the pancreas.

NIH Rare Diseases:42 Pancreatic cancer occurs when cells of the pancreas grow abnormally to form a tumor. the pancreas is a gland that normally makes juices that help break down food and produces insulin and other hormones. pancreatic cancer usually doesn't cause symptoms right away, but can cause yellowing of the skin and eyes, pain in the abdomen and back, weight loss, and fatigue. some risk factors for developing pancreatic cancer include smoking, long-term diabetes, chronic pancreatitis, and certain hereditary disorders. because pancreatic cancer is often found late and it spreads quickly, it can be hard to treat. possible treatments include surgery, radiation, and chemotherapy. last updated: 9/17/2013

MedlinePlus:32 The pancreas is a gland behind your stomach and in front of your spine. it produces the juices that help break down food and the hormones that help control blood sugar levels. pancreatic cancer usually begins in the cells that produce the juices. some risk factors for developing pancreatic cancer include smoking long-term diabetes chronic pancreatitis certain hereditary disorders pancreatic cancer is hard to catch early. it doesn't cause symptoms right away. when you do get symptoms, they are often vague or you may not notice them. they include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. possible treatments include surgery, radiation, chemotherapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

Wikipedia:64 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Description from OMIM:46 613347

Related Diseases for Pancreatic Cancer

About this section

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 3
Pancreatic Cancer 4

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 273)
idRelated DiseaseScoreTop Affiliating Genes
1pancreatitis33.5KRAS, BRCA2, SMAD4
2adenocarcinoma31.6BRCA2, TP53, SCTR, TNFRSF10B, SMAD4, BRCA1
3melanoma31.4TNFRSF10B, TP53, BRCA2, MMP2, STK11, PLAU
4lynch syndrome31.1BRCA2, BRCA1
5colorectal cancer31.0SMAD4, TNFRSF10B, TP53, MMP2, PLAU, KRAS
6cystadenoma31.0BRCA1, KRAS
7prostate cancer30.9EGFR, PLAU, MMP2, SMAD4
8li-fraumeni syndrome30.9TP53, BRCA2, BRCA1
9breast cancer30.9BRCA1, TP53
10hereditary breast ovarian cancer30.9BRCA2
11polyposis, juvenile intestinal30.8SMAD4, STK11
12adenoma30.8PPARG, SMAD4, TNFRSF10B, TP53, BRCA1, STK11
13cholangiocarcinoma30.8KRAS, TP53, SMAD4
14retinoblastoma30.7PPARG, SMAD4, TP53, BRCA2, BRCA1, KRAS
15glioblastoma30.7PPARG, SMAD4, TNFRSF10B, TP53, MMP2, PLAU
16endometrial cancer30.7TP53, BRCA2, BRCA1, MMP2, KRAS, EGFR
17leukemia30.6TNFRSF10B, TP53, BRCA2, BRCA1, KRAS, SLC29A1
18laryngeal carcinoma30.6EGFR, PLAU, MMP2, TP53
19sarcoma30.6TNFRSF10B, TP53, BRCA2, KRAS
20lung cancer30.5PPARG, TP53, STK11, KRAS, EGFR
21endotheliitis10.8
22hypoxia10.8
23autoimmune pancreatitis10.7
24brca1 and brca2 hereditary breast and ovarian cancer10.7BRCA2, BRCA1
25papillary carcinoma10.7BRCA2, SMAD4, PPARG
26giant cell glioblastoma10.7EGFR
27pancreatitis, hereditary10.7SMAD4, BRCA1, KRAS
28dysplastic nevus syndrome10.7PALLD, BRCA2
29fallopian tube cancer10.7BRCA2, BRCA1
30peritoneal carcinoma10.7BRCA2, BRCA1
31bilateral breast cancer10.6BRCA2, BRCA1
32pulmonary fibrosis10.6PPARG, MMP2, PLAU
33cowden disease10.6STK11, BRCA1, BRCA2, SMAD4
34biliary tract neoplasm10.6SMAD4, EGFR
35colon adenocarcinoma10.6KRAS, PLAU, SMAD4
36conjunctivochalasis10.6MMP2, PLAU
37exanthem10.6KRAS, EGFR
38dysgerminoma10.6BRCA1, BRCA2
39bronchiolo-alveolar adenocarcinoma10.6KRAS, EGFR
40duodenitis10.5
41ovarian cancer, somatic10.5SMAD4, TNFRSF10B, TP53, BRCA2, BRCA1, MMP2
42insulin-like growth factor i10.5
43autosomal dominant disease10.5BRCA1, STK11
44burkitt lymphoma10.5SMAD4, TNFRSF10B, TP53, BRCA2, KLF10, KRAS
45breast ductal carcinoma10.5SMAD4, TP53, BRCA1, PLAU, EGFR
46stomach cancer10.5SMAD4, TP53, MMP2, PLAU, KRAS, EGFR
47osteosarcoma, somatic10.5SMAD4, TNFRSF10B, TP53, MMP2, PLAU, KLF10
48pancreas disease10.5SCTR, SMAD4
49malignant glioma10.5SMAD4, TNFRSF10B, TP53, MMP2, PLAU, EGFR
50glioblastoma multiforme10.5TNFRSF10B, TP53, MMP2, PLAU, EGFR

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to pancreatic cancer

Symptoms for Pancreatic Cancer

About this section

Symptoms by clinical synopsis from OMIM:

260350

Clinical features from OMIM:

260350,613347

HPO human phenotypes related to Pancreatic Cancer:

id Description Frequency HPO Source Accession
1 neoplasm of the pancreas HP:0002894

Drugs & Therapeutics for Pancreatic Cancer

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Afinitor13 38 EVEROLIMUS Novartis Approved March 2009
FDA Label: Afinitor
Malady that Drug Treats: renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumor
Indications and Usage:13 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:11 Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the; PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular; protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of; mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation; factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate of; mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independent; activation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and; reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown; to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.; Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitro; studies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,; and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activity; of everolimus in a synergistic manner.; Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).; Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,; inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
2
Gemzar13 38 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
FDA Label: Gemzar
Malady that Drug Treats: pancreatic cancer/Lung cancer
Indications and Usage:13 Gemzar® is a nucleoside metabolic inhibitor indicated:; in combination with carboplatin, for the treatment of advanced ovarian; cancer that has relapsed at least 6 months after completion of platinumbased; therapy (1.1); in combination with paclitaxel, for first-line treatment of metastatic; breast cancer after failure of prior anthracycline-containing adjuvant; chemotherapy, unless anthracyclines were clinically contraindicated; (1.2); in combination with cisplatin for the treatment of non-small cell lung; cancer (1.3); as a single agent for the treatment of pancreatic cancer (1.4)
DrugBank Targets:11 1. DNA; 2. Ribonucleoside-diphosphate reductase large subunit; 3. Thymidylate synthase; 4. UMP-CMP kinase
Mechanism of Action:13 
Target: ribonucleotide reductase
Action: inhibitor
FDA: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary.; Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine; diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside; triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine; triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action; of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine; nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results in; the initiation of apoptotic cell death.
3
SecreFlo13 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen Approved April 2002
FDA Label: SecreFlo
Malady that Drug Treats: Pancreatic dysfunction and gastrinoma
Indications and Usage:13 SecreFlo is indicated for use in secretin stimulation testing for:; (1) Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of; pancreatic exocrine dysfunction,; (2) Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma.
DrugBank Targets:11 1. Secretin receptor
Mechanism of Action:13 
Target: secreted pancreatic juices
Action: increase volume and bicarbonate content
FDA: The primary action of SecreFlo is to increase the volume and bicarbonate content of; secreted pancreatic juices. The standard unit of activity used for SecreFlo is the clinical; unit defined by Jorpes & Mutt in 1966. (1) In the validated cat bioassay, which was used; to define and quantitate the biological activity of secretin and as the release test for the; biologically derived porcine secretin product, SecreFlo demonstrates a potency of; approximately 5000 clinical units (CU) per milligram of peptide as opposed to 3000 CU; per mg for biologically derived porcine secretin. As a pure peptide drug product,; SecreFlo"! dosing is expressed by weight in micrograms. The relationship of; micrograms of secretin to biological activity is 0.2 mcg = 1 CU.
4
Sutent13 38 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
FDA Label: Sutent
Malady that Drug Treats: pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:13 SUTENT is a kinase inhibitor indicated for the treatment of:; Gastrointestinal stromal tumor (GIST) after disease progression on or; intolerance to imatinib mesylate. (1.1); Advanced renal cell carcinoma (RCC). (1.2); Progressive, well-differentiated pancreatic neuroendocrine tumors; (pNET) in patients with unresectable locally advanced or metastatic; disease. (1.3)
DrugBank Targets:11 1. Platelet-derived growth factor receptor beta; 2. Vascular endothelial growth factor receptor 1; 3. Mast/stem cell growth factor receptor Kit; 4. Vascular endothelial growth factor receptor 2; 5. Vascular endothelial growth factor receptor 3; 6. Receptor-type tyrosine-protein kinase FLT3; 7. Macrophage colony-stimulating factor 1 receptor; 8. Platelet-derived growth factor receptor alpha
Mechanism of Action:13 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are; implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was; evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor; of platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and; cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary; metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.; Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRbð, VEGFR2, KIT) in tumor xenografts; expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or; inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit; growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit; PDGFRbð- and VEGFR2-dependent tumor angiogenesis in vivo.
5
Tarceva13 38 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals Approved November, 2004
FDA Label: Tarceva
Malady that Drug Treats: Non-small cell lung cancer
Indications and Usage:13 TARCEVA is a kinase inhibitor indicated for:; First-line treatment of patients with metastatic non-small cell lung; cancer (NSCLC) whose tumors have epidermal growth factor receptor; (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as; detected by an FDA-approved test. (1.1); Maintenance treatment of patients with locally advanced or metastatic; NSCLC whose disease has not progressed after four cycles of platinumbased; first-line chemotherapy. (1.1); Treatment of locally advanced or metastatic NSCLC after failure of at; least one prior chemotherapy regimen. (1.1); First-line treatment of patients with locally advanced, unresectable or; metastatic pancreatic cancer, in combination with gemcitabine. (1.2)
DrugBank Targets:11 1. Epidermal growth factor receptor; 2. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:13 
Target: Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase
Action: inhibitor
FDA: Epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells. In some tumor cells signaling; through this receptor plays a role in tumor cell survival and proliferation irrespective of EGFR mutation status. Erlotinib reversibly; inhibits the kinase activity of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor and thereby; inhibiting further downstream signaling. Erlotinib binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations is higher; than its affinity for the wild type receptor. Erlotinib inhibition of other tyrosine kinase receptors has not been fully characterized.

Drug clinical trials:

Search ClinicalTrials for Pancreatic Cancer

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Pancreatic Cancer

About this section

Genetic tests related to Pancreatic Cancer:

id Genetic test Affiliating Genes
1 Familial Pancreatic Cancer20
2 Carcinoma of Pancreas22
3 Pancreatic Cancer 222
4 Familial Pancreatic Carcinoma22

Anatomical Context for Pancreatic Cancer

About this section

MalaCards organs/tissues related to Pancreatic Cancer:

31
Pancreas, Endothelial, Skin, Eye, Breast, Colon, Liver, Testes, Lymph node, T cells, Bone, Prostate, Lung, Neutrophil, Monocytes, Myeloid, Bone marrow, Brain, Pituitary, Kidney, Thyroid, Testis, Nk cells, Pancreatic islet, Skeletal muscle

FMA organs/tissues related to Pancreatic Cancer:

14
The pancreas

Animal Models for Pancreatic Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Pancreatic Cancer:

35 (show all 27)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:001076811.2STK11, ACVR1B, PLAU, KRAS, RBBP8, EGFR
2MP:000538411.2KRAS, RBBP8, EGFR, TP53, KLF10, PLAU
3MP:000363111.2STK11, ACVR1B, PLAU, KRAS, EGFR, SLC29A1
4MP:000200611.2KLF10, EGFR, RBBP8, KRAS, PLAU, STK11
5MP:000538011.2STK11, ACVR1B, KRAS, RBBP8, EGFR, SMAD4
6MP:000538711.2RBBP8, KRAS, PPARG, SMAD4, SCTR, TP53
7MP:000537811.1EGFR, PPARG, SLC29A1, KRAS, PLAU, ACVR1B
8MP:000537611.1PPARG, SCTR, TNFRSF10B, SMAD4, PLAU, EGFR
9MP:000287311.1BRCA2, BRCA1, HOXB2, PPARG, SMAD4, TP53
10MP:000539711.1SCTR, TNFRSF10B, SMAD4, PPARG, TP53, BRCA2
11MP:000536911.1HOXB2, PPARG, TP53, BRCA1, EGFR, KRAS
12MP:000537911.1TP53, KRAS, PLAU, BRCA2, ACVR1B, STK11
13MP:001077111.0BRCA2, EGFR, KRAS, KLF10, TP53, SMAD4
14MP:000539011.0HOXB2, FAM3C, TP53, PPARG, MMP2, EGFR
15MP:000538911.0STK11, BRCA2, PPARG, SMAD4, BRCA1, TP53
16MP:000538111.0SMAD4, KRAS, EGFR, PLAU, ACVR1B, STK11
17MP:000538811.0KRAS, PLAU, ACVR1B, STK11, MMP2, TP53
18MP:000538610.9TP53, STK11, KRAS, BRCA1, BRCA2, SLC29A1
19MP:000536710.9KRAS, EGFR, STK11, TP53, BRCA1, SCTR
20MP:000539110.9HOXB2, PPARG, TP53, MMP2, STK11, KRAS
21MP:000538510.9PPARG, SMAD4, TP53, BRCA1, MMP2, PLAU
22MP:000538210.8ACVR1B, EGFR, PLAU, HOXB2, STK11, MMP2
23MP:000537010.7EGFR, KRAS, PLAU, TP53, SMAD4, STK11
24MP:000301210.7TNFRSF10B, STK11, SLC29A1, EGFR, ACVR1B, TP53
25MP:000118610.6EGFR, KRAS, BRCA1, TP53
26MP:000537110.5BRCA2, BRCA1, TP53, EGFR, KLF10, KRAS
27MP:000537510.3TP53, EGFR, PPARG, BRCA1, PLAU

Publications for Pancreatic Cancer

About this section

Articles related to Pancreatic Cancer:

(show top 50)    (show all 3461)
idTitleAuthorsYear
1
Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors. (24025713)
2014
2
Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. (25402324)
2014
3
Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. (23555989)
2013
4
Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. (23299404)
2013
5
High Intensity Focused Ultrasound Treatment for Patients with Local Advanced Pancreatic Cancer. (24088318)
2013
6
Biochanin A reduces pancreatic cancer survival and progression. (24201306)
2013
7
Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. (23598278)
2013
8
Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them? (24294503)
2013
9
MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway. (23519249)
2012
10
Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. (21811892)
2012
11
Invasive markers identified by gene expression profiling in pancreatic cancer. (22487523)
2012
12
Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. (22900040)
2012
13
Diagnostic Strategy for Differentiating Autoimmune Pancreatitis From Pancreatic Cancer: Is an Endoscopic Retrograde Pancreatography Essential? (22228050)
2012
14
Expression of miR-216a in pancreatic cancer and its clinical significance]. (23174591)
2012
15
High level of PTEN expression is associated with low-grade liver metastasis and satisfactory patient survival in pancreatic cancer. (22036936)
2011
16
Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1I+ under normoxic condition. (21320746)
2011
17
Activation of Na+/H+ exchanger 1 by neurotensin signaling in pancreatic cancer cell lines. (20138826)
2010
18
Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer. (19506533)
2009
19
Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth. (19610136)
2009
20
NIK is involved in constitutive activation of the alternative NF-kappaB pathway and proliferation of pancreatic cancer cells. (19646419)
2009
21
Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. (18646007)
2008
22
Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. (18544997)
2008
23
Geminin is overexpressed in human pancreatic cancer and downregulated by the bioflavanoid apigenin in pancreatic cancer cell lines. (18404646)
2008
24
Role of BRCA1 and BRCA2 mutations in pancreatic cancer. (16973716)
2007
25
Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). (16540233)
2007
26
Construction of targeted plasmid vector pcDNA3.1-Egr.1p-p16 and its expression in pancreatic cancer JF305 cells induced by radiation in vitro. (17696250)
2007
27
Increased S100A4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer. (16865243)
2006
28
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. (16568310)
2006
29
MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. (16721789)
2006
30
3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. (16332727)
2006
31
Hereditary pancreatitis and secondary screening for early pancreatic cancer. (16358943)
2005
32
Survivin expression and its clinical significance in pancreatic cancer. (16202147)
2005
33
Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. (15705601)
2005
34
Overexpression of TGF-beta by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer. (15365564)
2004
35
CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. (14749473)
2004
36
NDRG2 expression and mutation in human liver and pancreatic cancers. (15526377)
2004
37
Adenovirus-mediated transfer of a truncated fibroblast growth factor (FGF) type I receptor blocks FGF-2 signaling in multiple pancreatic cancer cell lines. (14707726)
2004
38
Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. (12900367)
2003
39
Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. (12594808)
2003
40
The genetics of pancreatic cancer. (12946833)
2003
41
Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. (12960962)
2003
42
Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. (11792148)
2002
43
Inflammation and the development of pancreatic cancer. (12020670)
2002
44
cAMP protection of pancreatic cancer cells against apoptosis induced by ERK inhibition. (11444827)
2001
45
Induction and expression of cyclin D3 in human pancreatic cancer. (11469683)
2001
46
In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organs. (11729853)
2000
47
Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. (9252195)
1997
48
Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. (8613430)
1996
49
Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. (8047987)
1994
50
Differential binding and biological activities of epidermal growth factor and transforming growth factor alpha in a human pancreatic cancer cell line. (1933884)
1991

Variations for Pancreatic Cancer

About this section

Clinvar genetic disease variations for Pancreatic Cancer:

5 (show all 27)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.105G> T (p.Leu35Phe)single nucleotide variantPathogenicrs121912661GRCh37Chr 17, 7579582: 7579582
2KRASNM_033360.3(KRAS): c.35G> A (p.Gly12Asp)single nucleotide variantPathogenic, drug responsers121913529GRCh37Chr 12, 25398284: 25398284
3KRASNM_033360.3(KRAS): c.35G> T (p.Gly12Val)single nucleotide variantPathogenic, drug responsers121913529GRCh37Chr 12, 25398284: 25398284
4PALB2NM_024675.3(PALB2): c.1027C> T (p.Gln343Ter)single nucleotide variantPathogenicrs180177097GRCh38Chr 16, 23635519: 23635519
5PALB2NM_024675.3(PALB2): c.1314delA (p.Phe440Leufs)deletionPathogenicrs515726065GRCh38Chr 16, 23635232: 23635232
6PALB2NM_024675.3(PALB2): c.172_175delTTGT (p.Gln60Argfs)deletionPathogenic, risk factorrs180177143GRCh38Chr 16, 23637886: 23637889
7PALB2PALB2: c.2515-1G> Tsingle nucleotide variantLikely pathogenic, Pathogenic, risk factorGRCh38Chr 16, 23629276: 23629276
8PALB2PALB2: c.3202-?_*297del (p.Gly1068_Ser1186delins45)deletionPathogenicGRCh38Chr 16, 23603162: 23603162
9PALB2NM_024675.3(PALB2): c.3256C> T (p.Arg1086Ter)single nucleotide variantPathogenic, risk factorGRCh38Chr 16, 23607958: 23607958
10PALB2NM_024675.3(PALB2): c.3497delG (p.Gly1166Valfs)deletionPathogenicrs180177138GRCh37Chr 16, 23614844: 23614844
11PALB2NM_024675.3(PALB2): c.509_510delGA (p.Arg170Ilefs)deletionPathogenicrs515726124GRCh38Chr 16, 23636036: 23636037
12PALB2NM_024675.3(PALB2): c.72delG (p.Arg26Glyfs)deletionPathogenicrs180177142GRCh38Chr 16, 23638106: 23638106
13PALB2NM_024675.3(PALB2): c.757_758delCT (p.Leu253Ilefs)deletionPathogenicrs180177092GRCh38Chr 16, 23635788: 23635789
14BRCA1NM_007294.3(BRCA1): c.68_69delAG (p.Glu23Valfs)deletionPathogenic, risk factorrs80357713GRCh37Chr 17, 41276047: 41276048
15BRCA1NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs)duplicationPathogenic, risk factorrs80357906GRCh37Chr 17, 41209083: 41209083
16SMAD4NM_005359.5(SMAD4): c.1236C> G (p.Tyr412Ter)single nucleotide variantPathogenicrs121912577GRCh37Chr 18, 48593485: 48593485
17PALLDNM_001166110.1(PALLD): c.415C> T (p.Pro139Ser)single nucleotide variantrisk factorrs121908291GRCh37Chr 4, 169799457: 169799457
18RBBP8NM_002894.2(RBBP8): c.1009A> G (p.Lys337Glu)single nucleotide variantPathogenicrs121434388GRCh37Chr 18, 20572799: 20572799
19STK11NM_000455.4(STK11): c.108C> A (p.Tyr36Ter)single nucleotide variantPathogenicrs137853079GRCh37Chr 19, 1207020: 1207020
20STK11NM_000455.4(STK11): c.650delC (p.Pro217Argfs)deletionPathogenicrs397518442GRCh37Chr 19, 1220632: 1220632
21STK11NM_000455.4(STK11): c.936delA (p.Lys312Asnfs)deletionPathogenicrs397518443GRCh37Chr 19, 1222999: 1222999
22ACVR1BNM_020328.3(ACVR1B): c.1282_1286delGATGA (p.Asp428Asnfs)deletionPathogenicrs387906389GRCh37Chr 12, 52380624: 52380628
23ACVR1BNM_020328.3: c.1385-502_1515+24del657deletionPathogenicGRCh37Chr 12, 52385145: 52385801
24SMAD4NM_005359.5(SMAD4): c.1072G> T (p.Gly358Ter)single nucleotide variantPathogenicrs121912576GRCh37Chr 18, 48591909: 48591909
25SMAD4NM_005359.5(SMAD4): c.1477G> C (p.Asp493His)single nucleotide variantPathogenicrs121912578GRCh37Chr 18, 48604655: 48604655
26SMAD4NM_005359.5(SMAD4): c.1543A> T (p.Arg515Ter)single nucleotide variantPathogenicrs121912579GRCh37Chr 18, 48604721: 48604721
27BRCA2NM_000059.3(BRCA2): c.5946delT (p.Ser1982Argfs)deletionPathogenic, risk factorrs80359550GRCh37Chr 13, 32914438: 32914438

Expression for genes affiliated with Pancreatic Cancer

About this section
Search GEO for disease gene expression data for Pancreatic Cancer.

Pathways for genes affiliated with Pancreatic Cancer

About this section

Pathways related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show top 50)    (show all 53)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.7TP53, EGFR, SMAD4, STK11, BRCA1, KRAS
210.7KRAS, STK11, BRCA1, BRCA2, TP53, SMAD4
3
Show member pathways
10.7SCTR, EGFR, KRAS, ACVR1B, SMAD4, TP53
410.7BRCA2, TP53, EGFR, KRAS, MMP2, SMAD4
5
Show member pathways
Signaling Pathways in Glioblastoma36
10.6MMP2, TP53, BRCA2, BRCA1, KRAS, EGFR
6
Show member pathways
10.6SMAD4, TP53, EGFR, BRCA2, KRAS
710.6STK11, TP53, EGFR, KRAS, BRCA1
8
Show member pathways
10.6PLAU, MMP2, PPARG, TP53, TNFRSF10B, EGFR
9
Show member pathways
10.6KRAS, ACVR1B, SMAD4, PPARG, EGFR
10
Show member pathways
10.6BRCA2, TP53, BRCA1, MMP2, EGFR
1110.6EGFR, KRAS, PLAU, BRCA1, TP53
1210.6TP53, PLAU, EGFR, MMP2, KRAS
13
Show member pathways
Transcription Receptor mediated HIF regulation59
Development CNTF receptor signaling59
Class IB PI3K non-lipid kinase events36
ErbB2/ErbB3 signaling events36
Development Growth hormone signaling via PI3K AKT and MAPK cascades59
Translation Regulation activity of EIF259
Regulation of lipid metabolism Insulin signaling generic cascades59
Transcription PPAR Pathway59
Cell adhesion PLAU signaling59
Translation Regulation activity of EIF4F59
10.6EGFR, STK11, PLAU, KRAS, PPARG
14
Show member pathways
10.6SMAD4, ACVR1B, TP53, BRCA1
15
Show member pathways
PLK2 and PLK4 events36
Polo-like kinase signaling events in the cell cycle36
10.6KRAS, STK11, SMAD4, EGFR
16
Show member pathways
10.6RBBP8, TP53, BRCA2, BRCA1
17
Show member pathways
10.6TP53, BRCA2, BRCA1, RBBP8
18
Show member pathways
Signal transduction PTEN pathway59
10.6SMAD4, TP53, KRAS, EGFR
19
Show member pathways
MAPK signaling pathway36
10.6ACVR1B, EGFR, KRAS, TP53
20
Show member pathways
10.6KRAS, EGFR, ACVR1B, TP53
21
Show member pathways
10.6PPARG, TP53, KRAS, ACVR1B
22
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
10.6TP53, PLAU, EGFR, KRAS
23
Show member pathways
10.6EGFR, ACVR1B, SMAD4, PPARG
2410.6MMP2, EGFR, TP53, TNFRSF10B
2510.6ACVR1B, KRAS, SMAD4
2610.6TP53, STK11, SMAD4
2710.6SMAD4, STK11, TP53
2810.6BRCA2, BRCA1, TP53
2910.6TP53, BRCA1, RBBP8
30
Show member pathways
Delta-Notch Signaling Pathway36
Notch Signaling Pathway36
10.6EGFR, SMAD4, TP53
3110.6PPARG, SMAD4, KRAS
3210.6EGFR, KRAS, TP53
3310.6EGFR, KRAS, TP53
34
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
10.6KRAS, EGFR, TP53
3510.6TP53, PLAU, SMAD4
36
Show member pathways
DNA damage response (only ATM dependent)36
Wnt Signaling Pathway and Pluripotency36
10.6SMAD4, TP53, PLAU
3710.6EGFR, BRCA1, SMAD4
3810.6KRAS, TP53, PPARG
39
Show member pathways
MAPK Cascade36
Immune response Oncostatin M signaling via MAPK in human cells59
Oncostatin M Signaling Pathway36
10.6TP53, PPARG, KRAS
40
Show member pathways
DNA damage response36
10.6TP53, BRCA1, TNFRSF10B
41
Show member pathways
10.6TNFRSF10B, BRCA1, TP53
4210.6BRCA1, RBBP8, PLAU
4310.6EGFR, TP53, MMP2
4410.5BRCA1, MMP2, PLAU
45
Show member pathways
Metalloproteases in connective tissue degradation
10.5MMP2, PLAU, EGFR
4610.5BRCA1, TP53
4710.5TP53, BRCA1
48
Show member pathways
EGFR-dependent Endothelin signaling events36
10.5EGFR, KRAS

Compounds for genes affiliated with Pancreatic Cancer

About this section

Compounds related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show top 50)    (show all 94)
idCompoundScoreTop Affiliating Genes
1serine4411.2STK11, TNFRSF10B, TP53, BRCA1, MMP2, SMAD4
2vegf4411.2EGFR, HOXB2, PPARG, SMAD4, TNFRSF10B, TP53
3estrogen4411.2SMAD4, EGFR, KRAS, KLF10, PLAU, BRCA1
4paraffin4411.2TP53, BRCA2, BRCA1, MMP2, STK11, KRAS
5retinoic acid44 2412.2HOXB2, TNFRSF10B, TP53, BRCA2, BRCA1, MMP2
6cycloheximide4411.1EGFR, PLAU, MMP2, BRCA1, TP53, TNFRSF10B
7paclitaxel44 50 1113.1TNFRSF10B, BRCA2, BRCA1, KRAS, EGFR, SLC29A1
85fluorouracil4411.1SLC29A1, EGFR, KRAS, MMP2, BRCA1, TP53
9thymidine44 2412.1PLAU, TNFRSF10B, SMAD4, SLC29A1, TP53, BRCA2
10cisplatin44 50 60 1114.1EGFR, BRCA1, PLAU, BRCA2, KRAS, TP53
11gemcitabine44 50 1113.1MMP2, SLC29A1, EGFR, BRCA1, TP53, TNFRSF10B
12h2o24411.1BRCA1, BRCA2, TP53, MMP2, KRAS, PLAU
13curcumin4411.0PLAU, TP53, PPARG, MMP2, TNFRSF10B, EGFR
14oxaliplatin44 50 1113.0BRCA1, EGFR, KRAS, TNFRSF10B, TP53
15adpribose4411.0BRCA1, BRCA2, TNFRSF10B, TP53, EGFR
16n acetylcysteine4411.0MMP2, PPARG, TNFRSF10B, EGFR, TP53, PLAU
17sb 20358044 6012.0PPARG, TP53, MMP2, PLAU, EGFR, SLC29A1
18alanine4411.0PPARG, SMAD4, STK11, ACVR1B, PLAU, BRCA1
19resveratrol44 60 24 1114.0BRCA2, BRCA1, MMP2, PPARG, TP53
20adriamycin4411.0BRCA2, BRCA1, PLAU, TNFRSF10B, TP53
21ly2940024411.0EGFR, KRAS, PLAU, MMP2, TP53, PPARG
22docetaxel44 50 60 1114.0PLAU, BRCA2, EGFR, TP53, BRCA1
23mg 13244 6012.0EGFR, BRCA1, SMAD4, TP53, TNFRSF10B
24genistein44 28 60 1 24 1116.0EGFR, PPARG, BRCA2, BRCA1, PLAU, MMP2
25topotecan44 1112.0TNFRSF10B, TP53, BRCA1, EGFR
26suberoylanilide hydroxamic acid4410.9EGFR, PPARG, TNFRSF10B, TP53
27etoposide44 50 60 1113.9TNFRSF10B, TP53, BRCA2, MMP2, BRCA1
28tamoxifen44 50 28 1113.9TP53, BRCA1, PLAU, EGFR, BRCA2
29progesterone44 28 60 24 1114.9EGFR, PLAU, MMP2, BRCA1, BRCA2, TP53
30bortezomib44 50 1112.9TP53, TNFRSF10B, BRCA1, EGFR
31celecoxib44 60 28 50 24 1115.9PPARG, MMP2, EGFR, TNFRSF10B
32irinotecan44 50 1112.9TP53, TNFRSF10B, KRAS, EGFR
33pdtc4410.9PPARG, TP53, MMP2, PLAU
34testosterone44 60 24 1113.9BRCA2, EGFR, PPARG, SMAD4, BRCA1, MMP2
355-methylcytosine44 2411.9BRCA1, TP53, STK11
36sp 60012544 6011.9TNFRSF10B, TP53, MMP2, PLAU
37thymidylate4410.9TP53, BRCA1, EGFR, SLC29A1
38sulindac sulfide4410.8PPARG, TP53, TNFRSF10B
39temozolomide44 1111.8EGFR, MMP2, TP53
40o6-methylguanine4410.8KRAS, BRCA2, TP53
41doxorubicin44 50 1112.8BRCA1, TP53, TNFRSF10B, PLAU, EGFR
42marimastat44 60 1112.8MMP2, EGFR, PLAU
43egcg4410.8EGFR, PLAU, TP53, MMP2
44proline4410.7MANF, MMP2, TP53, BRCA1, BRCA2
45crcs4410.7KRAS, SMAD4, TP53
46phosphatidylinositol4410.7BRCA1, MMP2, PLAU, KRAS, EGFR, BRCA2
47glycerol44 24 1112.6BRCA1, PPARG, MMP2, PLAU
48indole-3-carbinol4410.6TP53, BRCA1, BRCA2
49sulindac44 1111.4TP53, TNFRSF10B, PPARG
50batimastat44 60 1112.2MMP2, EGFR, PLAU

GO Terms for genes affiliated with Pancreatic Cancer

About this section

Cellular components related to Pancreatic Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1plasma membraneGO:000588610.7SCTR, BRCA1, MMP2, ACVR1B, PLAU, KRAS
2nucleusGO:000563410.5EGFR, HOXB2, PPARG, SMAD4, TP53, BRCA2

Biological processes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of transcription from RNA polymerase II promoterGO:004594411.0PPARG, TP53, SMAD4, EGFR, ACVR1B, BRCA1
2negative regulation of cell growthGO:003030811.0TP53, STK11, ACVR1B, PPARG, SMAD4
3positive regulation of transcription, DNA-templatedGO:004589311.0TP53, BRCA2, BRCA1, SMAD4, PPARG
4negative regulation of transcription from RNA polymerase II promoterGO:000012210.9KLF10, TP53, SMAD4, PPARG, RBBP8
5DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.9TP53, BRCA2, BRCA1
6double-strand break repair via homologous recombinationGO:000072410.9BRCA1, BRCA2, RBBP8
7double-strand break repairGO:000630210.9TP53, BRCA1, BRCA2
8cell proliferationGO:000828310.9EGFR, SMAD4, TP53, KLF10
9negative regulation of cell proliferationGO:000828510.9KLF10, STK11, SMAD4, TP53
10response to lipidGO:003399310.8PPARG, STK11
11transforming growth factor beta receptor signaling pathwayGO:000717910.8KLF10, TP53, SMAD4
12positive regulation of cell cycle arrestGO:007115810.8TP53, BRCA1
13response to X-rayGO:001016510.8TP53, BRCA2
14regulation of apoptotic processGO:004298110.8BRCA1, TP53, TNFRSF10B
15intrinsic apoptotic signaling pathway by p53 class mediatorGO:007233210.7STK11, TP53
16negative regulation of transcription, DNA-templatedGO:004589210.7PPARG, BRCA1, SMAD4, TP53
17positive regulation of transforming growth factor beta receptor signaling pathwayGO:003051110.7STK11, SMAD4
18response to hypoxiaGO:000166610.7MMP2, PLAU, SMAD4
19protein autophosphorylationGO:004677710.6ACVR1B, EGFR, STK11
20negative regulation of protein catabolic processGO:004217710.5SMAD4, EGFR
21positive regulation of DNA repairGO:004573910.5EGFR, BRCA1
22G2 DNA damage checkpointGO:003157210.4RBBP8, BRCA1
23cellular response to DNA damage stimulusGO:000697410.3BRCA1, TP53, STK11

Molecular functions related to Pancreatic Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:000551511.0EGFR, PPARG, SMAD4, TNFRSF10B, TP53, BRCA2
2transcription regulatory region DNA bindingGO:004421210.7PPARG, SMAD4, TP53, BRCA1
3ubiquitin protein ligase bindingGO:003162510.6ACVR1B, BRCA1, TP53
4LRR domain bindingGO:003027510.5KRAS, STK11
5enzyme bindingGO:001989910.5PPARG, TP53, BRCA1, EGFR
6chromatin bindingGO:000368210.3EGFR, TP53, SMAD4, PPARG

Sources for Pancreatic Cancer

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet